Zhang Xinjie, Wang Jiao, Dove Abigail, Yu Ting, Li Qiang, Gottesman Rebecca F, Xu Weili
Department of Pediatric Neurosurgery, West China Second University Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.
Neurology. 2025 Sep 23;105(6):e214033. doi: 10.1212/WNL.0000000000214033. Epub 2025 Aug 20.
The association between metabolic syndrome (MetS) and incident Parkinson disease (PD) remains equivocal. We aimed to investigate the association of MetS and its components with the risk of PD and to explore the role of genetic background in the MetS-PD association.
This prospective cohort study included PD-free adults aged 37-73 years from the UK Biobank. MetS was defined as presence of 3 or more of the following: elevated waist circumference (≥102 cm for men; ≥88 cm for women), hypertension (systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use of antihypertensive medication), dyslipidemia (high-density lipoprotein cholesterol <1.04 mmol/L for men or <1.30 mmol/L for women or use of lipid-lowering medication), hypertriglyceridemia (triglycerides ≥1.70 mmol/L or use of lipid-lowering medication), and hyperglycemia (HbA1c ≥ 5.7%). PD was diagnosed based on information from medical records. PD-related polygenic risk score (PRS) was calculated based on the presence of 26 PD-related alleles and categorized as low, moderate, or high. Data were analyzed using Cox regression. In addition, a meta-analysis was conducted by integrating the present UK Biobank data with findings from 8 other observational studies.
The study included 467,200 participants (mean age 56.53 ± 8.09 years; 54.26% female), 177,407 (37.97%) of whom had MetS. Over the follow-up (6,605.9 × 1,000 person-years), 3,222 participants developed PD (5.01 [95% CI 4.84-5.18] per 10,000 person-years, age-specified and sex-specified). The hazard ratio of PD was 1.39 (1.11-1.74) for participants with MetS compared with those who were MetS-free. Furthermore, having a higher number of MetS components was dose-dependently associated with higher PD risk (HR: 1.14 [1.05-1.24]; for trend = 0.001). In addition, PD risk was highest among participants with MetS and high PRS (HR: 2.58 [2.12-3.14]; for interaction = 0.002). In a meta-analysis of 24,789,538 participants with 98,582 incident cases of PD, the pooled relative risk of PD was 1.29 (1.15-1.44) for participants with MetS.
Supported by evidence from meta-analysis, MetS was associated with higher risk of incident PD, especially in people with a high genetic predisposition for PD.
代谢综合征(MetS)与帕金森病(PD)发病之间的关联仍不明确。我们旨在研究MetS及其各组分与PD风险的关联,并探讨遗传背景在MetS-PD关联中的作用。
这项前瞻性队列研究纳入了英国生物银行中37至73岁无PD的成年人。MetS定义为具备以下3项或更多情况:腰围增加(男性≥102 cm;女性≥88 cm)、高血压(收缩压≥130 mmHg,舒张压≥85 mmHg,或使用降压药物)、血脂异常(男性高密度脂蛋白胆固醇<1.04 mmol/L或女性<1.30 mmol/L,或使用降脂药物)、高甘油三酯血症(甘油三酯≥1.70 mmol/L或使用降脂药物)以及高血糖(糖化血红蛋白≥5.7%)。根据病历信息诊断PD。基于26个与PD相关的等位基因存在情况计算PD相关多基因风险评分(PRS),并分为低、中、高三个类别。使用Cox回归分析数据。此外,通过将当前英国生物银行数据与其他8项观察性研究结果进行整合,开展了一项荟萃分析。
该研究纳入467,200名参与者(平均年龄56.53±8.09岁;54.26%为女性),其中177,407名(37.97%)患有MetS。在随访期间(6,605.9×1,000人年),3,222名参与者发生了PD(每10,000人年5.01[95%CI 4.84 - 5.18],按年龄和性别分层)。与无MetS的参与者相比,患有MetS的参与者发生PD的风险比为1.39(1.11 - 1.74)。此外,MetS组分数量越多,与PD风险越高呈剂量依赖性相关(HR:1.14[1.05 - 1.24];趋势P = 0.001)。此外,在患有MetS且PRS高的参与者中,PD风险最高(HR:2.58[2.12 - 3.14];交互作用P = 0.002)。在一项对24,789,538名参与者和98,582例PD发病病例的荟萃分析中,患有MetS的参与者发生PD的合并相对风险为1.29(1.15 - 1.44)。
荟萃分析的证据支持MetS与PD发病风险较高相关,尤其是在具有较高PD遗传易感性的人群中。